Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track

Executive Summary

Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.

Advertisement

Related Content

Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel